Thromboelastographic Results and Hypercoagulability Syndrome in Patients With Coronavirus Disease 2019 Who Are Critically Ill

Absract

Introduction
Severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) is responsible for the coronavirus
disease 2019 (COVID-19) pandemic that has caused approximately 300 000 deaths globally.
Disseminated intravascular coagulopathy and other COVID-19–associated coagulopathies occur
among patients with severe SARS-CoV-2 infections.1 Potentially lethal hypercoagulability is an
unusual, poorly defined COVID-19–associated coagulopathy presentation.2,3We found that more
than half of patients admitted to the intensive care unit (ICU) of Baylor St Luke’s Medical Center
developed clinically significant thromboses that were associated with hypercoagulable
thromboelastographic (TEG) parameters alone.